Business Description
OncoCyte Corp
NAICS : 541380
SIC : 8734
ISIN : US68235C2061
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.29 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.26 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -6.02 | |||||
Beneish M-Score | -3.15 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.2 | |||||
3-Year EBITDA Growth Rate | 31.3 | |||||
3-Year EPS without NRI Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 28.1 | |||||
3-Year Book Growth Rate | -36.5 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.49 | |||||
Quick Ratio | 1.49 | |||||
Cash Ratio | 1.31 | |||||
Days Sales Outstanding | 388.31 | |||||
Days Payable | 375.85 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -33.7 | |||||
Shareholder Yield % | -33.89 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 27.48 | |||||
Operating Margin % | -1491.48 | |||||
Net Margin % | -1848.37 | |||||
FCF Margin % | -1551.9 | |||||
ROE % | -79.9 | |||||
ROA % | -32.54 | |||||
ROIC % | -30.83 | |||||
ROC (Joel Greenblatt) % | -164.06 | |||||
ROCE % | -16.48 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 14.24 | |||||
PB Ratio | 1.13 | |||||
EV-to-EBIT | -2.59 | |||||
EV-to-EBITDA | -2.99 | |||||
EV-to-Revenue | 21.77 | |||||
EV-to-FCF | -1.33 | |||||
Earnings Yield (Greenblatt) % | -38.58 | |||||
FCF Yield % | -59.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
OncoCyte Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1.503 | ||
EPS (TTM) ($) | -3.55 | ||
Beta | -0.02 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 82.6 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 82.6 - 82.6 | ||
Shares Outstanding (Mil) | 13.36 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
OncoCyte Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
OncoCyte Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
OncoCyte Corp Frequently Asked Questions
What is OncoCyte Corp(LTS:0KCC)'s stock price today?
When is next earnings date of OncoCyte Corp(LTS:0KCC)?
Does OncoCyte Corp(LTS:0KCC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |